Blood vessels are not static pipes. During development, and indeed whenever tissues grow or repair themselves, vascular networks must be extensively remodeled: new sprouts extend into avascular territory, redundant branches regress, and existing vessels adapt their caliber and shape to match the demands of blood flow. In the central nervous system, this orchestration is guided in part by Wnt signaling, a family of pathways with two major branches. The canonical Wnt/β-catenin branch is well established as a regulator of endothelial specialization and of the blood–brain barrier, the selective fortress that shields neural tissue from the bloodstream. The non-canonical Wnt/Planar Cell Polarity (PCP) branch, by contrast, is known to govern vascular remodeling and the ability of endothelial cells to sense and adapt to the mechanical forces of flowing blood. What has remained stubbornly unclear is how the PCP pathway—activated at the cell surface—translates its instructions into the internal polarity machinery that tells a cell which way is forward.

The new study, led by Cécile Duplàa and Thierry Couffinhal of Inserm unit UMR1034 at the University of Bordeaux, with contributions from Alexandre Dubrac at the Sainte-Justine Research Center and Université de Montréal, answers that question by zeroing in on MCC, short for Mutated in Colorectal Cancer. MCC is a PDZ-domain protein, a class of scaffold molecules that physically assemble signaling complexes at specific cellular locations. It had previously been implicated in cell migration in epithelial cells and identified as an effector of non-canonical Wnt signaling during convergence and extension movements in zebrafish embryos—developmental processes that depend intimately on planar cell polarity. The Bordeaux team, building on their laboratory’s long-standing interest in vascular morphogenesis, hypothesized that MCC might perform an analogous role inside endothelial cells.

The researchers’ mechanistic work centered on a striking molecular partnership. Using proximity-dependent biotinylation (BioID), a technique that maps proteins sitting close to a protein of interest within living cells, combined with mass spectrometry proteomics, they found that MCC interacts with CEP131, a component of centriolar satellites. Centriolar satellites are electron-dense granules that cluster around the centrosome—the cell’s principal microtubule-organizing center—and help regulate centrosome function, protein turnover and cilia biology. The team’s proteomics data, deposited in the ProteomeXchange Consortium, show that MCC does not merely associate with CEP131; it actively promotes the satellite protein’s degradation, engaging both the proteasome, the cell’s cytosolic protein-shredding machinery, and autophagy, the lysosomal degradation system often used for bulk recycling of cellular components. In other words, MCC functions as a quality-control switch for the structures surrounding the centrosome.

Why would this matter for polarity? The answer lies in the geometry of a migrating endothelial cell. To move directionally, a cell must establish a front–rear axis: the microtubule cytoskeleton and the microtubule-organizing center must be positioned and oriented toward the leading edge, while the Golgi apparatus and nucleus reposition accordingly. Previous work from several groups, including studies showing that excess centrosomes scatter and derail endothelial migration, had established that centrosome-associated organization is a linchpin of directional movement. By keeping centriolar satellite material in check through regulated turnover, MCC appears to preserve the clean, polarized centrosomal architecture that directional migration demands. When the researchers depleted MCC from endothelial cells, this organization fell apart—and with it, the cells’ ability to polarize front-to-back.

One of the most intriguing findings of the study is what did not fall apart. When the team subjected MCC-depleted endothelial cells to flow, mimicking the shear stress that blood exerts on vessel walls in vivo, the cells still elongated and aligned their cytoskeletons with the direction of flow—indeed, this flow-induced elongation was preserved and even enhanced. This dissociation is biologically revealing. It demonstrates that two processes often lumped together as “endothelial alignment” are mechanistically separable: the passive morphological response to fluid shear, in which cells stretch along the flow axis, can proceed without MCC, while the active, directional front–rear polarization required for guided migration depends on it. For vascular biologists, this functional split offers a new framework for dissecting how vessels respond to hemodynamic forces.

The in vivo evidence came from the postnatal mouse retina, a classic and visually tractable model of angiogenesis in which a vascular plexus expands radially across the retinal surface during the first weeks of life, driven by proliferating “tip” cells at the angiogenic front. When the researchers deleted the Mcc gene specifically in endothelial cells of newborn mice, the retinal vasculature failed to remodel properly. Vessel density was abnormal, endothelial proliferation dropped, and—critically—the front–rear polarity of endothelial cells at the angiogenic front was disrupted. Tip cells, which must polarize and migrate persistently to lead the vascular sprout, lost their organizational bearings.

To rule out the possibility that these polarity defects were merely secondary consequences of a grossly malformed vasculature, the team employed an elegant pharmacological intervention. Captopril, an angiotensin-converting enzyme inhibitor long used as a blood pressure drug, is known to normalize vascular density and promote vessel regression in the remodeling retina. When the researchers treated the MCC-deficient mice with captopril, vascular density normalized and pruning proceeded—but endothelial polarity remained broken. This result is pivotal: it indicates that MCC’s role is cell-intrinsic. The protein is not simply required to generate a vascular environment in which polarity is possible; it is required within each endothelial cell to construct the polarity machinery itself.

The study also situates MCC within a broader signaling hierarchy. Prior work by the Bordeaux group and collaborators had identified the E3 ubiquitin ligase PDZRN3 as a Wnt/PCP pathway component required for vascular morphogenesis, and proteomic analyses had placed PDZRN3 downstream of Wnt5a–Ror signaling, a prototypical non-canonical Wnt cascade. The new findings extend this wiring: MCC now emerges as a downstream effector that converts PCP pathway activity into centrosome-associated proteostasis—the controlled degradation of satellite components—thereby closing the gap between a signal received at the membrane and a polarized cytoskeleton inside the cell.

Beyond developmental biology, the work carries implications for human disease. MCC was originally named for its frequent mutation in colorectal tumors, and it has since been characterized as a putative tumor suppressor that represses β-catenin-dependent transcription. Its newly described role in endothelial biology suggests that alterations in MCC could contribute to vascular pathologies as well. Aberrant angiogenesis and defective vascular remodeling underlie a wide range of conditions, from diabetic retinopathy—where neurovascular crosstalk fails and vessels in the retina deteriorate—to ischemic disease, where therapeutic revascularization is limited by the vessels’ inability to remodel productively. Cerebral small vessel disease, another area of active investigation by members of the consortium, may also intersect with pathways controlling endothelial polarity and mechanosensing. If the MCC–CEP131 axis proves druggable, it could offer a handle for promoting or restraining vascular remodeling in clinical contexts.

The technical breadth of the study is itself noteworthy. The team combined live-cell polarity assays and automated image analysis, single-cell RNA sequencing of mouse retina—data publicly available through the Gene Expression Omnibus under accession GSE175895—and quantitative proteomics to characterize the MCC interactome. Such multi-omics integration is increasingly the norm in vascular biology, where the behavior of a single endothelial cell must be understood simultaneously at the level of gene expression, protein interaction networks and subcellular architecture.

For the field, the study fills a genuine conceptual hole. The Wnt/PCP pathway has been implicated in angiogenesis for nearly two decades, with components such as Celsr1, DAAM1 and Kif26b variously shown to regulate endothelial junctions, proliferation and polarity. Yet the route from pathway activation at the plasma membrane to the microtubule-organizing center has remained speculative. By identifying MCC as the bridge—and by showing that the bridge is built from regulated protein degradation at the centrosome—the Bordeaux-led consortium has supplied both the missing connection and a mechanistic explanation for why it matters. As vascular biologists now probe how this axis operates in pathological angiogenesis and in the mature vasculature of the adult brain, MCC may shed its reputation as merely a cancer gene and take on a new identity: a master organizer of the cell’s sense of direction.

Vascular remodeling is a hallmark process underlying numerous cardiovascular diseases, including hypertension, atherosclerosis, and aneurysms. It involves complex structural alterations within blood vessels, often triggered by pathological stimuli, leading to the thickening or stiffening of vessel walls. The detailed mechanisms steering these changes have long eluded scientists, impeding the development of targeted therapies. Now, the elucidation of EHMT2’s role sheds light on a pivotal epigenetic regulator that aggravates these remodeling processes.

EHMT2, also known as G9a, is a histone methyltransferase that catalyzes the dimethylation of histone H3 lysine 9 (H3K9me2), thus modulating chromatin structure and gene expression. Historically recognized primarily for its functions in development and cancer biology, EHMT2 has now emerged as a critical epigenetic effector within vascular smooth muscle cells (VSMCs). Its overexpression correlates with pathological remodeling, suggesting that EHMT2’s enzymatic activity represses genes vital for maintaining vascular integrity.

Among the genes suppressed by EHMT2, GADD45G—a stress-responsive gene known for its role in DNA repair, cell cycle arrest, and apoptosis—stands out. The research presents compelling evidence that EHMT2-mediated histone methylation at the GADD45G promoter leads to its epigenetic silencing. This downregulation impairs the cell’s ability to respond adequately to vascular stress, thereby fostering maladaptive remodeling and disease progression.

The team employed a multifaceted approach combining in vitro experiments with in vivo vascular injury models to delineate this pathway. They observed that knocking down EHMT2 significantly restored GADD45G expression levels, which in turn attenuated pathological changes in vascular structure. This functional rescue underscores the therapeutic potential of targeting EHMT2 in vascular diseases characterized by aberrant remodeling.

Further mechanistic studies revealed that EHMT2 is recruited to the GADD45G locus through interactions with other chromatin remodeling factors, establishing a repressive complex that consolidates the epigenetic silencing effect. This insight not only deepens our understanding of gene regulation in VSMCs but also highlights new epigenetic landscapes susceptible to pharmacological intervention.

The clinical implications of these findings are profound. Vascular remodeling contributes to the morbidity and mortality of cardiovascular diseases worldwide. By pinpointing EHMT2 as a key culprit in this process, the study invites the development of selective EHMT2 inhibitors as novel therapeutics that can reverse or prevent harmful vascular changes. Unlike traditional therapies that target symptoms, epigenetic modulators offer the allure of disease modification at a molecular level.

Moreover, the specificity of EHMT2’s action on GADD45G suggests that targeting this axis could minimize off-target effects, a common hurdle in epigenetic therapy. The research team advocates for subsequent clinical studies to evaluate the safety and efficacy of EHMT2 inhibitors in human vascular disease cohorts, envisioning a future where epigenetic drugs complement existing cardiovascular treatments.

This pivotal work aligns with the burgeoning recognition of epigenetics in cardiovascular research. While genetic factors undeniably contribute to disease susceptibility, epigenetic modifications dynamically respond to environmental cues and pathological stress. EHMT2’s modulation within this framework exemplifies how external and internal factors converge to orchestrate vascular fate decisions.

Additionally, the study’s innovative use of genome-wide chromatin immunoprecipitation sequencing (ChIP-seq) to map EHMT2 binding sites across the vascular genome uncovers a broader regulatory network. The identification of other epigenetically regulated genes involved in inflammation, proliferation, and extracellular matrix remodeling opens avenues for future investigations into comprehensive epigenetic therapies.

The discovery also raises intriguing questions about the interplay between EHMT2 and other histone modifiers or non-coding RNAs in vascular cells. It prompts reevaluation of the epigenomic complexity that governs vascular remodeling and the potential for combinatorial therapies targeting multiple epigenetic layers.

Importantly, the research underscores the value of epigenetic biomarkers in predicting disease progression. Monitoring EHMT2 expression or H3K9me2 levels in vascular tissues or circulating cells could inform prognostic assessments and therapeutic responses, advancing personalized medicine paradigms in cardiovascular care.

In the broader context, this study exemplifies the integration of molecular biology, epigenetics, and vascular medicine to unravel disease mechanisms that were previously inscrutable. It bridges fundamental science with translational potential, echoing the paradigm shift towards precision intervention targeting the epigenome to combat chronic diseases.

As cardiovascular diseases continue to impose a heavy global burden, insights from this research ignite hope for innovative treatments that transcend symptom management to achieve true disease modification. The epigenetic inhibition of protective genes like GADD45G by EHMT2, as delineated by Wang et al., marks a seminal moment in vascular biology that could redefine therapeutic strategies in the years to come.

Subject of Research: Epigenetic regulation of vascular remodeling, specifically the role of EHMT2 in suppressing GADD45G leading to pathological vascular changes.

Article Title: EHMT2 aggravates vascular remodeling via epigenetic inhibition of GADD45G.

Article References:
Wang, Z., Zhao, J., Luo, W. et al. EHMT2 aggravates vascular remodeling via epigenetic inhibition of GADD45G. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01702-6

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01702-6

Vascular remodeling is an adaptive response often triggered by chronic pressure overload, as seen in hypertension and heart failure. This process involves structural alterations in blood vessel walls, including thickening and stiffening, driven largely by the phenotypic switch of VSMCs from a contractile to a synthetic state. Such phenotypic modulation results in enhanced cellular proliferation, migration, and extracellular matrix secretion, which collectively impair vascular functionality. Despite its clinical significance, the molecular underpinnings governing this phenotypic plasticity have remained elusive until now.

At the heart of this study is USP13, a ubiquitin-specific protease known for its ability to remove ubiquitin molecules from protein substrates, thereby regulating their stability and activity. By employing a sophisticated combination of in vitro and in vivo models, the team demonstrated that USP13 expression is upregulated in VSMCs subjected to mechanical stress mimicking pressure overload. This upregulation correlates with increased vascular remodeling and the transition of VSMCs toward a pathogenic synthetic phenotype.

Crucially, the mechanistic breakthrough of the research lies in the identification of Beclin-1, an autophagy-regulating protein, as a direct substrate of USP13. The researchers showed that USP13 deubiquitinates Beclin-1, shielding it from proteasomal degradation and thereby maintaining elevated autophagy activity within VSMCs under stress. Autophagy, the cellular recycling system, is already known to modulate cell survival and phenotype, but its precise role in vascular remodeling has been controversial. This study convincingly positions autophagic flux, regulated by Beclin-1 stability, as a key driver of VSMC phenotypic transition.

Experimentally, the team utilized pressure overload models in rodents, inducing hypertensive conditions that mimic human disease. They observed that knocking down USP13 expression significantly alleviated the vascular thickening and fibrosis typically seen in these models. Conversely, overexpression of USP13 intensified pathological remodeling, underscoring its direct contribution to disease progression. These results not only validate the pathological role of USP13 but also put forward its potential as a therapeutic target.

At the cellular level, the study delineates how USP13-mediated Beclin-1 stabilization enhances VSMC proliferation and migration. This is significant because these cellular behaviors are central to maladaptive vascular remodeling. The findings that autophagic activity supports these phenotypic changes provide a new perspective on the sometimes dualistic nature of autophagy in vascular biology—highlighting that context is crucial when considering autophagy modulation as a therapeutic approach.

Extending beyond vascular pathology, the identification of USP13 as a crucial modulator of Beclin-1 stability also has broad implications for diseases where autophagy is dysregulated. Given that autophagy plays roles in cancer, neurodegeneration, and cardiovascular disease, the regulatory influence of USP13 could position it as a key molecular hub in diverse pathological processes. This insight opens avenues for cross-disease therapeutic development based on modulating USP13 activity.

From a molecular perspective, the study adds to the growing understanding of the ubiquitin–proteasome system (UPS) in vascular disease. The UPS is fundamental to cellular protein homeostasis, and its dysregulation leads to numerous disorders. USP13’s role as a deubiquitinase indicates that enzymes within this system can specifically govern crucial signaling molecules like Beclin-1, fine-tuning autophagic responses and cell fate decisions. This layer of regulation, often overshadowed by research focused on ubiquitin ligases, demands greater attention moving forward.

Methodologically, the researchers employed an impressive suite of molecular biology techniques. These included co-immunoprecipitation assays demonstrating direct USP13-Beclin-1 interaction, ubiquitination assays confirming deubiquitinating activity, and functional assays assessing VSMC phenotypic markers in response to mechanical stimuli. Complementing these mechanistic experiments, in vivo blood pressure measurements and histological analyses provided physiological relevance. This comprehensive approach strengthens the confidence in the conclusions drawn.

The translational potential of these findings cannot be overstated. Hypertension and its consequences represent one of the leading causes of morbidity and mortality worldwide. Therapeutic strategies targeting USP13-mediated pathways could revolutionize treatment paradigms, moving beyond symptomatic blood pressure control toward arresting or even reversing vascular damage. Furthermore, specific inhibitors or modulators of USP13 function could offer a novel class of therapeutics with potentially fewer side effects than current broad-spectrum interventions.

Interestingly, this study challenges pre-existing notions that simply enhancing autophagy is universally beneficial in cardiovascular contexts. It reveals that when autophagy is dysregulated through USP13-mediated stabilization of Beclin-1, it may exacerbate harmful vascular remodeling. Therefore, future therapies will require nuanced modulation—possibly temporal or tissue-specific targeting of USP13 or Beclin-1—to achieve optimal outcomes without unintended consequences.

Looking ahead, the authors advocate for further investigation into USP13’s regulation and its interplay with other deubiquitinases or ubiquitin ligases in vascular cells. Additionally, exploring how USP13 expression and activity change in human hypertensive patients will be critical for translating these findings clinically. There may also be a need to examine whether USP13 influences other autophagy-related or unrelated pathways contributing to vascular pathology.

In conclusion, Qi, Xie, Su, and their team have illuminated a vital regulatory mechanism in pressure overload-induced vascular remodeling by linking USP13-driven deubiquitination and stabilization of Beclin-1 to phenotypic transitions in VSMCs. Their work not only deepens the molecular understanding of vascular disease but also proposes USP13 as a promising target for innovative therapies that address the underlying pathology rather than just clinical symptoms. As hypertension continues to pose global health challenges, such molecular insights provide hope for more effective, targeted interventions.

Subject of Research: The role of USP13 in pressure overload-induced vascular remodeling and phenotypic transition of vascular smooth muscle cells through regulation of Beclin-1.

Article Title: USP13 facilitates pressure overload induced vascular remodeling and phenotypic transition of VSMCs via deubiquitinating Beclin-1.

Article References:
Qi, RQ., Xie, QF., Su, LH. et al. USP13 facilitates pressure overload induced vascular remodeling and phenotypic transition of VSMCs via deubiquitinating Beclin-1. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-025-02931-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02931-w